论文部分内容阅读
目的:探讨阿托伐他汀治疗缺血性卒中后的近期疗效和安全性。方法:缺血性卒中患者148例随机分为试验组(n=75)和对照组(n=73),试验组在常规治疗基础上,每天加用阿托伐他汀20 mg,每天晚上睡前服用1次,连续服用18周,观察血脂改变、缺血性卒中复发和不良反应。结果:试验组与对照组比较,对降低总胆固醇、低密度脂蛋白胆固醇和三酰甘油有统计学显著性差异(P<0.05),不良反应无明显增加(P>0.05)。结论:对于缺血性卒中患者,阿托伐他汀20 mg能更有效地使低密度脂蛋白胆固醇和总胆固醇达标,同时对降低三酰甘油,升高高密度脂蛋白胆固醇也具有较好的效果,不良反应无明显增加。
Objective: To investigate the short-term efficacy and safety of atorvastatin in the treatment of ischemic stroke. Methods: One hundred and eighty-eight patients with ischemic stroke were randomly divided into experimental group (n = 75) and control group (n = 73). The experimental group was given daily atorvastatin 20 mg daily, Take 1 time, taking 18 consecutive weeks, observed changes in blood lipids, ischemic stroke recurrence and adverse reactions. Results: Compared with the control group, there was a significant difference (P <0.05) between the experimental group and the control group in reducing total cholesterol, low density lipoprotein cholesterol and triglyceride, and no significant increase in adverse reactions (P> 0.05). CONCLUSIONS: Atorvastatin 20 mg is more effective in achieving LDL cholesterol and total cholesterol in patients with ischemic stroke, and also has a good effect in lowering triglycerides and increasing high-density lipoprotein cholesterol , No significant increase in adverse reactions.